Nektar Therapeutics Shares Outstanding 2006-2019 | NKTR

Nektar Therapeutics shares outstanding from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Nektar Therapeutics Annual Shares Outstanding
(Millions of Shares)
2018 180
2017 156
2016 140
2015 132
2014 127
2013 116
2012 115
2011 113
2010 94
2009 93
2008 92
2007 92
2006 90
2005 86
Nektar Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
Q2 2019 175
Q1 2019 174
Q4 2018 180
Q3 2018 173
Q2 2018 182
Q1 2018 161
Q4 2017 156
Q3 2017 163
Q2 2017 155
Q1 2017 154
Q4 2016 140
Q3 2016 137
Q2 2016 136
Q1 2016 136
Q4 2015 132
Q3 2015 133
Q2 2015 132
Q1 2015 136
Q4 2014 127
Q3 2014 132
Q2 2014 127
Q1 2014 124
Q4 2013 116
Q3 2013 116
Q2 2013 116
Q1 2013 115
Q4 2012 115
Q3 2012 115
Q2 2012 115
Q1 2012 115
Q4 2011 113
Q3 2011 114
Q2 2011 114
Q1 2011 109
Q4 2010 94
Q3 2010 94
Q2 2010 94
Q1 2010 94
Q4 2009 93
Q3 2009 93
Q2 2009 93
Q1 2009 93
Q4 2008 92
Q3 2008 92
Q2 2008 92
Q1 2008 92
Q4 2007 92
Q3 2007 92
Q2 2007 92
Q1 2007 91
Q4 2006 90
Q3 2006 90
Q2 2006 90
Q1 2006 89
Q4 2005 86
Q3 2005 86
Q2 2005 85
Q1 2005 85
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $3.188B $1.193B
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the company's wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $59.064B 36.38
Takeda Pharmaceutical (TAK) Japan $26.341B 8.22
Astellas Pharma (ALPMY) Japan $26.215B 12.85
UCB SA (UCBJF) Belgium $15.008B 0.00
Grifols, S.A (GRFS) Spain $15.002B 19.14
Eisai (ESALY) Japan $14.332B 24.64
Merck (MKGAF) Germany $13.654B 18.63
Ionis Pharmaceuticals (IONS) United States $9.481B 20.45
Ono Pharmaceutical (OPHLF) Japan $9.383B 20.06
Neurocrine Biosciences (NBIX) United States $8.689B 0.00
IPSEN SA ADR (IPSEY) France $8.520B 0.00
Sage Therapeutics (SAGE) United States $8.318B 0.00
Catalent (CTLT) United States $8.054B 32.32
Jazz Pharmaceuticals (JAZZ) Ireland $7.439B 9.79
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $7.257B 19.83
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.781B 0.00
STADA ARZNEIMI (STDAF) Germany $5.547B 0.00
Orion OYJ (ORINY) Finland $5.275B 27.16
Hypermarcas (HYPMY) Brazil $4.735B 17.02
FibroGen (FGEN) United States $3.750B 93.78
United Therapeutics (UTHR) United States $3.487B 0.00
Tilray (TLRY) Canada $3.415B 0.00
Evotec AG (EVTCY) Germany $3.120B 42.71
Taro Pharmaceutical Industries (TARO) Israel $3.103B 11.12
Arrowhead Pharmaceuticals (ARWR) United States $2.767B 63.44
PTC Therapeutics (PTCT) United States $2.614B 0.00
Xencor (XNCR) United States $2.284B 49.79
Portola Pharmaceuticals (PTLA) United States $2.085B 0.00
Zogenix (ZGNX) United States $2.057B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.621B 59.00
CLINIGEN GP (CLIGF) United Kingdom $1.577B 0.00
USANA Health Sciences (USNA) United States $1.452B 14.56
Corcept Therapeutics (CORT) United States $1.439B 19.78
Ironwood Pharmaceuticals (IRWD) United States $1.404B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.384B 22.84
Heron Therapeutics (HRTX) United States $1.349B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.205B 0.00
Aerie Pharmaceuticals (AERI) United States $1.129B 0.00
Radius Health (RDUS) United States $1.040B 0.00
ArQule (ARQL) United States $1.039B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.837B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $0.718B 3.20
TherapeuticsMD (TXMD) United States $0.716B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.552B 0.00
Karyopharm Therapeutics (KPTI) United States $0.545B 0.00
Concordia (CXRXF) Canada $0.533B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.518B 0.00
Akebia Therapeutics (AKBA) United States $0.511B 0.00
Endo (ENDP) Ireland $0.505B 0.89
Aptorum Group (APM) China $0.477B 0.00
Indivior (INVVY) United States $0.466B 1.68
Crinetics Pharmaceuticals (CRNX) United States $0.437B 0.00
Dermira (DERM) United States $0.430B 0.00
Dova Pharmaceuticals (DOVA) United States $0.427B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.421B 19.12
ImmunoGen (IMGN) United States $0.412B 0.00
Siga Technologies (SIGA) United States $0.411B 0.96
Flexion Therapeutics (FLXN) United States $0.409B 0.00
Translate Bio (TBIO) United States $0.405B 0.00
ChemoCentryx (CCXI) United States $0.376B 0.00
Innate Pharma SA (IPHYF) France $0.374B 0.00
Collegium Pharmaceutical (COLL) United States $0.366B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.354B 0.00
Organogenesis Holdings (ORGO) United States $0.326B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.322B 0.00
CV Sciences (CVSI) United States $0.317B 0.00
Xeris Pharmaceuticals (XERS) United States $0.292B 0.00
Harpoon Therapeutics (HARP) United States $0.286B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.285B 0.00
CannTrust Holdings (CTST) Canada $0.280B 0.00
KalVista Pharmaceuticals (KALV) United States $0.280B 0.00
Rafael Holdings (RFL) United States $0.269B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.256B 0.00
Lannett Co Inc (LCI) United States $0.255B 2.48
DURECT (DRRX) United States $0.250B 0.00
OptiNose (OPTN) United States $0.249B 0.00
Concert Pharmaceuticals (CNCE) United States $0.244B 0.00
Recro Pharma (REPH) United States $0.241B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.219B 0.00
Calithera Biosciences (CALA) United States $0.210B 0.00
Ocular Therapeutix (OCUL) United States $0.199B 0.00
Molecular Templates (MTEM) United States $0.186B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.176B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.176B 0.00
Taiwan Liposome (TLC) Taiwan $0.175B 0.00
Nature's Sunshine Products (NATR) United States $0.174B 29.03
Redhill Biopharma (RDHL) Israel $0.147B 0.00
IMV INC (IMV) Canada $0.140B 0.00
Ardelyx (ARDX) United States $0.135B 0.00
GlycoMimetics (GLYC) United States $0.132B 0.00
Jounce Therapeutics (JNCE) United States $0.130B 0.00
Generex Biotechnology (GNBT) United States $0.128B 0.00
Majesco Entertainment (PTE) United States $0.119B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.117B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.113B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.107B 0.00
MEI Pharma (MEIP) United States $0.106B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.104B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.098B 0.00
AgeX Therapeutics (AGE) United States $0.098B 0.00
Iterum Therapeutics (ITRM) Ireland $0.094B 0.00
Mast Therapeutics (SVRA) United States $0.092B 0.00
Aquestive Therapeutics (AQST) United States $0.088B 0.00
Neos Therapeutics (NEOS) United States $0.088B 0.00
Cardiome Pharma (CORV) Canada $0.085B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.085B 32.41
Genocea Biosciences (GNCA) United States $0.082B 0.00
Natural Alternatives (NAII) United States $0.076B 7.62
RENEURON GP (RNUGF) United Kingdom $0.075B 0.00
MediWound (MDWD) Israel $0.074B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.074B 0.00
Nivalis Therapeutics (ALPN) United States $0.071B 0.00
Champions Oncology (CSBR) United States $0.069B 598.00
Infinity Pharmaceuticals (INFI) United States $0.068B 0.00
China SXT Pharmaceuticals (SXTC) China $0.068B 0.00
Otonomy (OTIC) United States $0.067B 0.00
Novan (NOVN) United States $0.065B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.063B 0.00
Pharmaxis (PXSLY) Australia $0.060B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.059B 0.00
SCYNEXIS (SCYX) United States $0.058B 0.00
Capnia (SLNO) United States $0.057B 0.00
Lipocine (LPCN) United States $0.053B 0.00
Medicure (MCUJF) Canada $0.053B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.053B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.046B 0.00
ElectroCore (ECOR) United States $0.045B 0.00
Forward Pharma (FWP) Denmark $0.044B 0.00
India Globalization Capital (IGC) United States $0.040B 0.00
CTI BioPharma (CTIC) United States $0.038B 0.00
Mannatechorporated (MTEX) United States $0.036B 0.00
Bio-Path Holdings (BPTH) United States $0.035B 0.00
Aclaris Therapeutics (ACRS) United States $0.033B 0.00
Melinta Therapeutics (MLNT) United States $0.032B 0.00
PharmAthene (ALT) United States $0.032B 0.00
Biomerica (BMRA) United States $0.030B 0.00
ProPhase Labs (PRPH) United States $0.023B 0.00
IsoRay (ISR) United States $0.021B 0.00
Opexa Therapeutics (ACER) United States $0.020B 0.00
Heat Biologics (HTBX) United States $0.019B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.018B 1.43
HANCOCK JAFFE (HJLI) United States $0.017B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.015B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.015B 0.00
Achieve Life Sciences (ACHV) United States $0.014B 0.00
Cyanotech (CYAN) United States $0.014B 0.00
Onconova Therapeutics (ONTX) United States $0.014B 0.00
Shineco (TYHT) China $0.013B 0.00
Regulus Therapeutics (RGLS) United States $0.012B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.011B 0.00
VAXART, INC (VXRT) United States $0.010B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.009B 0.00
RXi Pharmaceuticals (PHIO) United States $0.009B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.007B 0.00
Jaguar Animal Health (JAGX) United States $0.006B 0.00
Flex Pharma (SLRX) United States $0.004B 0.00
Midatech Pharma (MTP) United Kingdom $0.004B 0.00
Can-Fite Biopharma (CANF) Israel $0.003B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.002B 0.00
Xenetic Biosciences (XBIO) United States $0.001B 0.00
Advanced Accelerator Applications S.A (AAAP) France $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00